Literature DB >> 22495544

Editorial commentary: should 13-valent protein-conjugate pneumococcal vaccine be used routinely in adults?

Daniel M Musher.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22495544     DOI： 10.1093/cid/cis364

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  18 in total

Review 1.  Pneumococcal vaccine and opsonic pneumococcal antibody.

Authors:  Joon Young Song; M Allen Moseley; Robert L Burton; Moon H Nahm
Journal:  J Infect Chemother       Date:  2013-05-09       Impact factor: 2.211

2.  Serotypes of Streptococcus pneumoniae in Egyptian children: are they covered by pneumococcal conjugate vaccines?

Authors:  M Badawy; A El Kholy; M M Sherif; E A Rahman; E Ashour; H Sherif; H E Mahmoud; M Hamdy
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-07-25       Impact factor: 3.267

3.  Pneumococcal Vaccination in Adults Aged ≥65 Years: Cost-Effectiveness and Health Impact in U.S. Populations.

Authors:  Angela R Wateska; Mary Patricia Nowalk; Chyongchiou J Lin; Lee H Harrison; William Schaffner; Richard K Zimmerman; Kenneth J Smith
Journal:  Am J Prev Med       Date:  2020-01-28       Impact factor: 5.043

4.  Cost-effectiveness of adult pneumococcal vaccination policies in underserved minorities aged 50-64 years compared to the US general population.

Authors:  Angela R Wateska; Mary Patricia Nowalk; Chyongchiou J Lin; Lee H Harrison; William Schaffner; Richard K Zimmerman; Kenneth J Smith
Journal:  Vaccine       Date:  2019-03-04       Impact factor: 3.641

Review 5.  Preventing pneumococcal disease in the elderly: recent advances in vaccines and implications for clinical practice.

Authors:  Angel Vila-Corcoles; Olga Ochoa-Gondar
Journal:  Drugs Aging       Date:  2013-05       Impact factor: 3.923

6.  Randomized controlled study of the safety and immunogenicity of pneumococcal vaccine formulations containing PhtD and detoxified pneumolysin with alum or adjuvant system AS02V in elderly adults.

Authors:  Karlis Pauksens; Anna C Nilsson; Magalie Caubet; Thierry G Pascal; Pascale Van Belle; Jan T Poolman; Pierre G Vandepapelière; Vincent Verlant; Peter E Vink
Journal:  Clin Vaccine Immunol       Date:  2014-03-05

Review 7.  Pneumococcal vaccination of older adults: conjugate or polysaccharide?

Authors:  David S Fedson; Martin J Guppy
Journal:  Hum Vaccin Immunother       Date:  2013-05-31       Impact factor: 3.452

8.  Effectiveness of vaccination with 23-valent pneumococcal polysaccharide vaccine in preventing hospitalization with laboratory confirmed influenza during the 2009-2010 and 2010-2011 seasons.

Authors:  Angela Domínguez; Jesús Castilla; Pere Godoy; Miguel Delgado-Rodríguez; Marc Saez; Núria Soldevila; Jenaro Astray; José María Mayoral; Vicente Martín; José María Quintana; Fernando González-Candelas; Juan Carlos Galán; Sonia Tamames; Ady Castro; Maretva Baricot; Olatz Garín; Tomas Pumarola
Journal:  Hum Vaccin Immunother       Date:  2013-04-01       Impact factor: 3.452

9.  U.S. hospitalizations for pneumonia after a decade of pneumococcal vaccination.

Authors:  Marie R Griffin; Yuwei Zhu; Matthew R Moore; Cynthia G Whitney; Carlos G Grijalva
Journal:  N Engl J Med       Date:  2013-07-11       Impact factor: 91.245

10.  Impact of Pneumococcal Conjugate Vaccine Administration in Pediatric Older Age Groups in Low and Middle Income Countries: A Systematic Review.

Authors:  Kimberly Bonner; Emily Welch; Kate Elder; Jennifer Cohn
Journal:  PLoS One       Date:  2015-09-02       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.